Number of Patients by Course
| . | Filgrastim . | Placebo . |
|---|---|---|
| Induction 1 | 259 | 262 |
| Induction 2 | 60 (23%) | 67 (26%) |
| Consolidation 1 | 162 (63%) | 157 (60%) |
| Consolidation 2 | 81 (31%) | 84 (32%) |
| DAV (2 + 5 + 5) | 60 (23%) | 58 (22%) |
| HD-Ara-C/DNR | 21 (8%) | 26 (10%) |
| . | Filgrastim . | Placebo . |
|---|---|---|
| Induction 1 | 259 | 262 |
| Induction 2 | 60 (23%) | 67 (26%) |
| Consolidation 1 | 162 (63%) | 157 (60%) |
| Consolidation 2 | 81 (31%) | 84 (32%) |
| DAV (2 + 5 + 5) | 60 (23%) | 58 (22%) |
| HD-Ara-C/DNR | 21 (8%) | 26 (10%) |
Abbreviations: DAV: daunorubicin, cytosine-arabinoside, etoposide; HD-Ara-C/DNR; high-dose cytosine-arabinoside/daunorubicin.